67165-56-4 Usage
Description
Diclofensine is a synthetic compound that acts as a stimulant and an antidepressant. It inhibits the reuptake of dopamine and noradrenaline, making it an effective treatment for depression. However, it is important to note that diclofensine exhibits significant addictive properties.
Uses
Used in Pharmaceutical Industry:
Diclofensine is used as an antidepressant for treating depression. It works by inhibiting the reuptake of dopamine and noradrenaline, which helps to improve mood and alleviate depressive symptoms.
Used as a Stimulant:
Due to its stimulant properties, diclofensine may also be used for other applications where increased alertness and energy are desired. However, its use in this context should be approached with caution due to its addictive potential.
Check Digit Verification of cas no
The CAS Registry Mumber 67165-56-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,7,1,6 and 5 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 67165-56:
(7*6)+(6*7)+(5*1)+(4*6)+(3*5)+(2*5)+(1*6)=144
144 % 10 = 4
So 67165-56-4 is a valid CAS Registry Number.
InChI:InChI=1/C17H17Cl2NO/c1-20-9-12-7-13(21-2)4-5-14(12)15(10-20)11-3-6-16(18)17(19)8-11/h3-8,15H,9-10H2,1-2H3
67165-56-4Relevant articles and documents
ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF
-
, (2010/12/17)
Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders. Methods of making these compounds are also described in the present invention.
CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
-
Page/Page column 33, (2010/12/17)
Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.